Philadelphia Trust Company’s Teva Pharmaceuticals TEVA Stock Holding History

Philadelphia Trust Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,340	Closed	-$273K	–	197
2015 Q4	$273K	Buy	+4,340	New	+$268K	0.02%	165
2015 Q3	–	Sell	-298	Closed	-$5.04K	–	182
2015 Q2	$5.04K	Sell	298 -4,747	-94%	-$293K	0.02%	160
2015 Q1	$314K	Buy	5,045 +37	+0.7%	+$2.15K	0.02%	151
2014 Q4	$288K	Sell	5,008 -2,250	-31%	-$125K	0.02%	143
2014 Q3	$390K	Sell	7,258 -525	-7%	-$27.8K	0.02%	135
2014 Q2	$408K	Sell	7,783 -353	-4%	-$18K	0.03%	130
2014 Q1	$430K	Buy	8,136 +75	+0.9%	+$3.47K	0.03%	136
2013 Q4	$323K	Hold	8,061	–	–	0.02%	163
2013 Q3	$305K	Hold	8,061	–	–	0.02%	154
2013 Q2	$316K	Buy	+8,061	New	+$314K	0.02%	145

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Philadelphia Trust Company's TEVA Position: Q1 2016 in Review

Philadelphia Trust Company sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 4,340 shares — an estimated $273K sold.

Philadelphia Trust Company first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $430K in Q1 2014. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Philadelphia Trust Company reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Philadelphia Trust Company sold 4,340 Teva Pharmaceuticals shares in Q1 2016, an estimated $273K.
Philadelphia Trust Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Philadelphia Trust Company's Teva Pharmaceuticals position peaked at $430K in Q1 2014.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Philadelphia Trust Company's 13F filing for Q1 2016, filed 13 May 2016.